Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.40 |
| ▸ | RXRA | P19793 | 4/20 | 0.35 |
| ▸ | RXRB | P28702 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MPL | P40238 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451812 | 0.92 | FFAR4 (0.41) | FFAR4RXRARXRBHTR1ADRD2 | |
| SCHEMBL4458992 | 0.85 | FFAR4 (0.35) | FFAR4HTR1ADRD2DRD4KCNH2 | |
| SCHEMBL29053049 | 0.81 | DRD4 (0.37) | HTR1ADRD2DRD4KCNH2LMNA | |
| SCHEMBL4458385 | 0.78 | RXRB (0.37) | FFAR4RXRARXRBHTR1ADRD2 | |
| SCHEMBL4466566 | 0.76 | KMO (0.38) | RXRARXRBRXRGRARG | |
| SCHEMBL4456613 | 0.74 | GPR119 (0.48) | THRB | |
| SCHEMBL786550 | 0.72 | RPS6KB1 (0.43) | KCNH2SCN9A | |
| SCHEMBL29136131 | 0.72 | RIPK1 (0.49) | DRD2KCNH2LMNA | |
| SCHEMBL16634470 | 0.70 | DRD2 (0.40) | DRD2DRD4 | |
| SCHEMBL3985447 | 0.70 | RIPK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | FFAR4 212/4885RXRA 202/4885RXRB 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.